U.S. Department of Defense's Committee on Tactical Combat Casualty Care (CoTCCC) updated its guideline recommendations to include HemCon's ChitoGauze hemostatic chitosan-coated gauze product.
WESTPORT, Conn., April 10, 2014 /PRNewswire/ -- HemCon Medical Technologies, Inc. ("HemCon"), a wholly owned subsidiary of TriStar Wellness Solutions(R), Inc. (OTCQB: TWSI) and a leading developer and marketer of advanced medical products, announced today that the U.S. Department of Defense's Committee on Tactical Combat Casualty Care (CoTCCC) updated its guideline recommendations for control of severe external hemorrhage to include HemCon's ChitoGauze hemostatic chitosan-coated gauze product.
Logo - http://photos.prnewswire.com/prnh/20140410/CL02397LOGO-a
Logo - http://photos.prnewswire.com/prnh/20140410/CL02397LOGO-b
In addition to its hemostatic effect, ChitoGauze also provides broad-spectrum antibacterial properties at the wound site; a feature that no other battlefield tested dressing offers. This capability assumes increasing relevance with the emergence of multi-drug resistant bacteria such as Acinetobacter baumannii and MRSA and their increasing incidence in military wounds.
"The official acknowledgment of ChitoGauze's efficacy given by the addition to the CoTCCC guidelines is a true testament to HemCon's dedication to always provide products that can help save lives," said Michael Wax, President and CEO of HemCon. "Being back on the protocol, following HemCon's original lyophilized HemCon Bandage tenure, will guarantee best-in-class hemostatic technology is available for our soldiers on the battlefield."
External hemorrhaging has been increasingly recognized as a major cause of preventable death following severe injury on the battlefield and in civilian settings. The ChitoGauze hemostatic dressing is now recognized across all U.S. Military Services for providing hemorrhage control after tourniquet or other recommended controls have failed. In published data by the Naval Medical Research Unit, San Antonio (NAMRU-SA), ChitoGauze controlled bleeding effectively in the standardized in-vivo U.S. Army Institute for Surgical Research (ISR) injury model with absence of foreign material in the wound. ChitoGauze has a proven track record in controlling hemorrhage in military and civilian trauma, and is being used successfully by emergency systems and hospitals across the United States as well as internationally.
The CoTCCC guidelines are based on evidence-based review of the medical literature and on pre-clinical studies conducted by the Naval Medical Research Center and the U.S. Army Institute for Surgical Research. The CoTCCC recommendations for treatment of traumatic bleeding are used across all U.S. Military Forces. The CoTCCC Guidelines are respected internationally with many allied and foreign military services incorporating the same guidelines within their own services. With regulatory approvals and a strong distribution network in place, HemCon anticipates broad sales of its life-saving ChitoGauze dressing within military services worldwide.
About HemCon Medical Technologies
HemCon Medical Technologies Inc., founded in 2001, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore. With a 36,000 sq. ft. state of the art manufacturing facility, the Company has additional commercial operations in Ireland and the Czech Republic. For more information, please visit www.hemcon.com.
About TriStar Wellness Solutions
TriStar Wellness Solutions®, Inc. (TWSI) is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beaute de Maman™ brand of women's health products. Additional information is available at www.tstarwellness.com.
Forward-Looking Statement
This press release for TriStar Wellness Solutions®, Inc. contains forward-looking statements. Generally, you can identify these statements because they use words like "anticipates," "believes," "expects," "future," "intends," "plans," and similar terms. These statements reflect only our current expectations. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy and actual results may differ materially from those we anticipated due to a number of uncertainties, many of which are unforeseen, including, among others, the risks we face as described our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements which apply only as of the date of this press release. To the extent that such statements are not recitations of historical fact, such statements constitute forward-looking statements that, by definition, involve risks and uncertainties. In any forward-looking statement where we express an expectation or belief as to future results or events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation of belief will be accomplished.
Contact:
Simona Buergi
Tel: (503) 245-0459
[email protected]
/Web site: http://www.tstarwellness.com
SOURCE TriStar Wellness Solutions
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article